Baird has initiated its coverage of newly IPO’d medical device maker Beta Bionics (NASDAQ:BBNX) with a Neutral recommendation ... said will help it improve its market share of new U.S. pump ...

Although the fund's convertible-arbitrage strategy is generally beta-neutral and benefits from equity market fluctuations, it is still vulnerable to a credit crisis like the one in 2008 and ...

Although the fund's convertible-arbitrage strategy is generally beta-neutral and benefits from equity market fluctuations, it is still vulnerable to a credit crisis like the one in 2008 and ...

The AGFiQ U.S. Market Neutral Anti-Beta ETF from AGF Management is a strategy fund that takes a 50 percent long position in low-beta U.S. stocks and a 50 percent short position in high-beta stocks.

with a Neutral rating and $20 price target The firm believes Beta’s iLet Bionic Pancreas is differentiated, and is bullish on the multi-year growth potential for the insulin pump market.

These funds also typically aim at attaining zero beta, i.e., the stock price’s movement in correlation to the market. The main objective is to reduce risk and not volatility, as market-neutral ...

Baird initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $20 price target ... TheFly – the ultimate source for real-time, market-moving breaking financial news.